Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Acrivon Therapeutics COO Eric Devroe sells $910 in stock

Acrivon Therapeutics COO Eric Devroe sells $910 in stock

Acrivon Therapeutics COO Eric Devroe sold 628 shares of the company's common stock on November 17, 2026. The transaction amounted to $910, with each share priced at $1.45. This sale occurred automatically to meet tax withholding obligations following the vesting of restricted stock units. The price represented the average cost of 4,070 shares sold by their broker, which covered the withholding tax liability for a group of the company's employees, including Mr. Devroe.

The remaining proceeds were distributed evenly among the employees. After completing the sale, Mr. Devroe now directly owns 145,721 shares of Acrivon Therapeutics common stock. Currently, the company's stock is trading at $1.40, close to its 52-week low of $1.27 and has dropped by 42% year-to-date. Despite the negative price trend, InvestingPro's analysis indicates that the stock is undervalued at its current price point, and the stock is featured on the platform's Most Undervalued list.

Acrivon Therapeutics maintains a fair financial health score and holds a greater cash reserve than debt on its balance sheet. Recently, Jefferies has reaffirmed its Buy rating on the company, setting a price target of $14.00. This decision was made following a key opinion leader event focused on Acrivon's inflammation and immunology research, particularly the development of ACR-525.

Management's follow-up to the event provided additional insights into the drug's development, which helped bolster Jefferies' confidence in the company's progress in drug development.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at investing.com →